Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia 12Lymphoma 2Leukemia, T-Cell 2Leukemia, Biphenotypic, Acute 2Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Glioblastoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Temozolomide 44Radiotherapy 16Bevacizumab 9Surgical Procedures, Operative 5Carmustine 5pembrolizumab 4Lomustine 4Drug Therapy 4Sunitinib 3Standard of Care 3Radiation 3Procarbazine 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3Chlorotoxin 3Carboplatin 3Blood Specimen Collection 3tislelizumab 2fludarabine 2camrelizumab 2Radiosurgery 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Hyperbaric Oxygenation 2Ethanol 2Cyclophosphamide 2Chemotherapy, Adjuvant 2CT-322 2Bortezomib 2Aminolevulinic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Glioblastoma × Mercaptopurine × Clear all
NCT06279767 2024-02-28

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Unknown
27 enrolled
CNS

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡